Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Receives NCI SBIR Grant to Develop In Vitro Liver Toxicity Assays

NEW YORK, Dec. 21 (GenomeWeb News) - Iconix Pharmaceuticals has won a Phase I SBIR grant from the National Cancer Institute to develop new cell-based methods for testing drug candidates for liver toxicity, the company said today.

 

The grant will allow the Mountain View, Calif.-based company to apply its chemogenomics technology to high-volume testing of drug candidates and environmental chemicals for their potential long-term effects on the liver. Iconix plans to develop in vitro patterns of genomic change that can be used as biomarkers of liver toxicity.

 

The amount of the grant was not immediately available from the company. The NIH database lists one six-month, $97,654 award for Iconix from the NCI this year entitled "Development of In Vitro Toxicity Expression Assays."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more